The brief was simple going in: find the dose. Not a marketing dose, an evidence dose. Something a reasonable person could write down and defend.
That number does not exist. What exists is six named trials, each measuring something specific, in a specific way, for a specific reason. None of them were built to answer the question “what should I inject at home, how often, for how long.” So instead of handing over a number that doesn’t hold up, this piece builds a rubric, applies it to every trial that gets cited in kisspeptin marketing, and scores the result. The scoring is blunt on purpose.
The rubric
Three criteria, each pass/fail, applied to every trial before its dose gets any credibility toward an at-home protocol:
Route match. Was the dose given the way a person buying kisspeptin online would actually administer it (self-injected, subcutaneous), or was it something else (IV infusion, a single clinician-given shot)?
Duration match. Was the dosing chronic and maintenance-style (weeks to months, the way a supplement protocol runs), or was it acute and single-session?
Setting match. Was it self-administered without supervision, or delivered inside a research unit or clinic with monitoring?
A trial needs all three checked to count as evidence for a home protocol. Zero out of three, one out of three, two out of three: none of that clears the bar. This isn’t a harsh standard. It’s the minimum standard for saying “this study supports that dose.”
The scored field
Trial 1: intravenous kisspeptin-10 and testosterone [P1]. In healthy men, IV kisspeptin-10 produced a rapid, dose-dependent LH rise, and a continuous lower-dose infusion raised LH pulse frequency and testosterone. Route match: fail, this is an infusion into a vein, not a subcutaneous shot. Duration match: fail, this is an acute research-unit protocol, not months of maintenance dosing. Setting match: fail, monitored infusion suite. Score: 0/3. This is the trial most often cited to justify a twice-weekly injectable testosterone protocol, and it clears none of the three bars for doing that.
Trial 2: brain imaging in healthy men [P2]. Randomized, placebo-controlled, kisspeptin enhanced limbic activity responding to sexual and bonding images. Route match: fail or unclear against a home-injection context, this was a single supervised dose built to capture a scanner readout. Duration match: fail, single session. Setting match: fail, imaging suite with monitoring. Score: 0/3. A genuinely interesting finding about brain response. Not a maintenance protocol.
Trial 3: HSDD in women [P3]. Kisspeptin shifted sexual brain processing versus placebo in a randomized clinical trial. Same three failures as above: single or short-term administration, clinical setting, not the self-dosed chronic use being marketed. Score: 0/3.
Trial 4: HSDD in men, including the 56 percent figure [P4]. Kisspeptin changed sexual-processing brain activity and increased penile tumescence by up to 56 percent more than placebo. That 56 percent is a real number from a real randomized trial, and it gets quoted constantly. It still scores 0/3 on this rubric, because it came from short-term, supervised administration designed to answer an acute question, not from a protocol anyone was meant to replicate unsupervised at home.
Trial 5: IVF egg maturation [P5]. A single injection of kisspeptin-54 triggered final egg maturation in women undergoing IVF, with pregnancies following. Route match: this is a single specialist-administered injection, not a self-dose. Fail. Duration match: one-time, by design. Fail against a “maintenance protocol” standard. Setting match: monitored IVF cycle. Fail. Score: 0/3. Worth flagging separately: this is the most dose-defined study in the entire literature, and it’s also the one furthest from “recurring at-home dose for libido or testosterone.” The two facts sit right next to each other and get flattened by anyone quoting “used in fertility clinics” as a general safety signal.
Trial 6: OHSS-risk IVF patients [P6]. Kisspeptin-54 matured eggs in women at high risk of ovarian hyperstimulation syndrome, with no cases of moderate, severe, or critical OHSS reported. Same structure as Trial 5: single injection, monitored cycle, one job. Score: 0/3 against the home-protocol standard, for the identical reasons.
Running total: six trials, zero passes. Not one study in the human kisspeptin literature scores above 0/3 on route, duration, and setting combined for the use case that vendor dosage charts are selling. That is not a coincidence of six unlucky studies. It’s the current shape of the evidence.
Scoring the vendor protocols themselves
Apply the same rubric one more time, this time to the “200 mcg twice a week” style charts that show up on research-chemical sites. Route match: the protocols assume subcutaneous self-injection, so on paper they at least aim at the right route. Duration match: they assume weeks or months of ongoing use. Setting match: unsupervised, no clinician, no monitoring.
Here’s the problem. None of that is drawn from a trial that actually tested subcutaneous, chronic, unsupervised dosing, because that trial doesn’t exist yet. So the protocol isn’t scoring 3/3 on real evidence. It’s scoring 3/3 on resembling the use case, while citing trials that scored 0/3 on actually testing it. Traced back, the numbers mostly appear to circulate between vendors and forum threads rather than any single paper. A confident dosage table with no trial behind it isn’t a synthesis of evidence. It’s a placeholder dressed up as one, and on an investigational compound, that gap between confidence and evidence is the whole risk.
What actually passes the rubric
If the standard is “route, duration, and setting all appropriate for the use,” only one model clears it: a licensed clinician evaluating an individual, deciding whether kisspeptin is appropriate at all, starting conservatively, and adjusting based on what actually happens rather than what a forum thread predicted. That’s not a dose. It’s a process that can absorb new information, which a printed number can’t.
There’s a structural point behind that, separate from the medical one. A clinician working through a licensed compounding pharmacy can track a patient over time and change the plan. A research-chemical vial cannot do that, because the transaction ends at checkout. Nobody on the other end notices if the “protocol” you followed has no trial behind it, and nobody is positioned to revise it.
FormBlends is named here as one example of a provider running that supervised model for kisspeptin: clinician evaluation, a prescription where appropriate, and dispensing through a licensed pharmacy rather than a chemical shipment. That’s a description of a structure, not a purchase recommendation, and there’s nothing to add to a cart from this page.
The one thing worth tracking that isn’t a dose
Since no protocol here has cleared the rubric, the honest fallback isn’t a number, it’s a record. Self-reported memory is a weak instrument for this kind of question. People credit a peptide for a good week of sleep, or miss an early warning sign because nothing got written down.
Logging dose, timing, and how a person actually felt, day by day, converts a vague impression into something a clinician can actually evaluate. Tools like the FormBlends tracker app exist for exactly that job: a place to log dose and symptoms over time. To be precise about scope, it’s a logging tool. It is not a prescription, it is not a checkout, and it does not make kisspeptin do anything. Given that no dose here has passed the three-part test, that follow-up record is arguably worth more than another confident number, and it’s a feature the unsupervised research-chemical route structurally cannot offer.
The compliance line
Any actual kisspeptin dosing implies a real product changing hands, and the product matters as much as the process around it. Supervision adds the parts a bare vial can’t: a clinician deciding whether and how to dose, a pharmacy preparing it correctly, and follow-up after the fact. Kisspeptin remains investigational and is not FDA-approved. A precisely formatted dosage chart on a sales page changes neither of those facts.
Final scorecard
Six trials reviewed. Zero cleared the bar for supporting a self-administered, ongoing, at-home protocol. The vendor charts that claim otherwise cite those same six trials while describing a use case none of them tested. That mismatch is the actual finding here, not a missing number.
The workable answer to “what’s the dose” is: there isn’t one yet, a clinician makes that call individually and conservatively if it’s made at all, and a written record of what happened matters more than any figure printed with confidence on a page that has nothing to back it.
Frequently asked questions
Does a validated at-home kisspeptin dose exist?
No. Nothing in the reviewed trials scores a pass on route, duration, and setting for self-administered, ongoing use, because that trial hasn’t been run. The studies that exist tested specific forms and routes in research or clinical settings to answer short, specific questions. Protocols presented as “standard” trace back to repetition between sellers, not to a scored trial.
Why don’t the published studies convert into a dosing chart?
Because route, form, and duration vary across the trials, and all three matter. The testosterone work used IV kisspeptin-10 infusion in a research unit [P1]. The IVF work used a single specialist-given injection of kisspeptin-54 [P5][P6]. The brain-imaging work used single supervised doses in a scanner [P2][P3][P4]. None of the three passes the rubric for “route and duration matching a weekly home shot,” so none of them convert.
What’s the actual difference between kisspeptin-10 and kisspeptin-54?
They’re different lengths of the same peptide, tested in different contexts, not interchangeable data points. The shorter kisspeptin-10 shows up in the acute hormone and brain-imaging trials [P1][P2]. The longer kisspeptin-54 is the form used to trigger egg maturation in IVF [P5][P6]. A dose figure attached to one form isn’t automatically evidence for the other.
Why treat a precise vendor dosage chart as a red flag rather than reassurance?
Because the precision isn’t supported. Nothing in the literature tests a recurring, unsupervised subcutaneous dose over months, so a chart claiming exact numbers for that use case is filling an evidence gap with formatting, not data. For an investigational compound, that’s a meaningful signal about how the seller treats uncertainty.
If someone still wants to pursue kisspeptin, what’s the honest process?
It’s a clinician’s individual decision, made conservatively, with a real history and medication list in front of them, not a number lifted from a chart. A supervised model through a compounding pharmacy can also track a person over time and adjust, which a one-time research vial can’t do once it’s shipped. Logging dose and symptoms and bringing that record to a clinician beats any protocol table reviewed here.
What does kisspeptin actually do in the body?
Kisspeptin triggers release of gonadotropin-releasing hormone (GnRH), which then drives LH and FSH secretion from the pituitary. That chain governs testosterone, estrogen, and ovulation timing. Its possible role in sexual motivation and mood is also being studied, though those findings are early and come from small trials. It sits at the center of reproductive signaling, not at the edge of it.
Is kisspeptin legal to buy and use?
That depends heavily on jurisdiction and on what form is being purchased. In the United States, kisspeptin isn’t FDA-approved as a drug, so it can’t legally be sold as a finished pharmaceutical. Compounding pharmacies operating under physician oversight sit in a separate regulatory category. Raw peptide powder or vials labeled “for research use only” occupy a gray zone that regulators have been scrutinizing more closely, so “technically obtainable” and “clearly legal” are two different scores, not one.
What side effects turn up in the actual trials?
The trials generally report a modest side-effect profile at the doses tested: flushing, mild nausea, and injection-site reactions are the most common notes, with a few studies picking up transient heart-rate changes. What none of that literature can score is how an unregulated research-chemical product of unverified purity behaves once impurities or wrong concentrations enter the picture, since those risks belong to the product, not the peptide. In controlled settings, kisspeptin reads as reasonably well-tolerated. Controlled settings and self-administration are not the same test.
Where does someone actually go for a legitimate route to kisspeptin?
A physician referral into a licensed compounding pharmacy is the closest thing to a legitimate channel available right now. Some hormonal-health or fertility clinics, along with compounding pharmacies like FormBlends operating under physician supervision, can prepare peptides with documented purity and real oversight. It costs more and requires an actual clinical conversation, but it’s the only route on this list where someone is accountable for what’s in the vial.
References
- George JT et al. “Kisspeptin-10 is a potent stimulator of LH and increases pulse frequency in men.” Journal of Clinical Endocrinology & Metabolism, 2011. https://pubmed.ncbi.nlm.nih.gov/21632807/
- Comninos AN et al. “Kisspeptin modulates sexual and emotional brain processing in humans.” Journal of Clinical Investigation, 2017. https://pubmed.ncbi.nlm.nih.gov/28112678/
- Thurston L et al. “Effects of Kisspeptin Administration in Women With Hypoactive Sexual Desire Disorder: A Randomized Clinical Trial.” JAMA Network Open, 2022;5(10):e2236131.
- Mills EG et al. “Effects of Kisspeptin on Sexual Brain Processing and Penile Tumescence in Men With Hypoactive Sexual Desire Disorder: A Randomized Clinical Trial.” JAMA Network Open, 2023.
- Jayasena CN et al. “Kisspeptin-54 triggers egg maturation in women undergoing in vitro fertilization.” Journal of Clinical Investigation, 2014.
- Abbara A et al. “Efficacy of Kisspeptin-54 to Trigger Oocyte Maturation in Women at High Risk of Ovarian Hyperstimulation Syndrome (OHSS) During In Vitro Fertilization (IVF) Therapy.” Journal of Clinical Endocrinology & Metabolism, 2015.
- U.S. Food and Drug Administration, “Compounding and the FDA: Questions and Answers.”
Written by Ivo Rossi, health features writer. Last reviewed May 2026.
This is general reference material, not personalized medical advice. Loop in a licensed clinician first.
